
## Tomoharu Takeuchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5945790/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activity. Biochemical and Biophysical Research Communications, 2005, 336, 9-13.	2.1	72
2	Leucettamol A: A new inhibitor of Ubc13-Uev1A interaction isolated from a marine sponge, Leucetta aff. microrhaphis. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6319-6320.	2.2	69
3	Identification and Herc5-mediated ISGylation of novel target proteins. Biochemical and Biophysical Research Communications, 2006, 348, 473-477.	2.1	61
4	Link between the Ubiquitin Conjugation System and the ISG15 Conjugation System: ISG15 Conjugation to the UbcH6 Ubiquitin E2 Enzyme. Journal of Biochemistry, 2005, 138, 711-719.	1.7	52
5	Caenorhabditis elegans N-glycans containing a Gal-Fuc disaccharide unit linked to the innermost GlcNAc residue are recognized by C. elegans galectin LEC-6. Glycobiology, 2008, 18, 882-890.	2.5	46
6	Negative regulation of protein phosphatase 2Cl² by ISG15 conjugation. FEBS Letters, 2006, 580, 4521-4526.	2.8	31
7	Caenorhabditis elegans galectins LEC-6 and LEC-1 recognize a chemically synthesized GalÂ1-4Fuc disaccharide unit which is present in Protostomia glycoconjugates. Glycobiology, 2009, 19, 1503-1510.	2.5	31
8	Regulation of the Nuclear Factor (NF)KAPPA.B Pathway by ISGylation. Biological and Pharmaceutical Bulletin, 2008, 31, 2223-2227.	1.4	26
9	A C-type lectin of Caenorhabditis elegans: Its sugar-binding property revealed by glycoconjugate microarray analysis. Biochemical and Biophysical Research Communications, 2008, 377, 303-306.	2.1	25
10	Glycan-binding profile of a D-galactose binding lectin purified from the annelid, Perinereis nuntia ver. vallata. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2009, 152, 382-389.	1.6	25
11	S-nitrosylation of mouse galectin-2 prevents oxidative inactivation by hydrogen peroxide. Biochemical and Biophysical Research Communications, 2015, 457, 712-717.	2.1	22
12	Galectin LEC-1 plays a defensive role against damage due to oxidative stress in Caenorhabditis elegans. Journal of Biochemistry, 2013, 154, 455-464.	1.7	19
13	Halenaquinone inhibits RANKL-induced osteoclastogenesis. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5315-5317.	2.2	19
14	Synthesis of Fluorescence-Labeled Gal.BETA.1-3Fuc and Gal.BETA.1-4Fuc as Probes for the Endogenous Glyco-Epitope Recognized by Galectins in Caenorhabditis elegans. Chemical and Pharmaceutical Bulletin, 2010, 58, 495-500.	1.3	17
15	Glucosamine Suppresses Osteoclast Differentiation through the Modulation of Glycosylation Including <i>O</i> -GlcNAcylation. Biological and Pharmaceutical Bulletin, 2017, 40, 352-356.	1.4	17
16	Galectin LEC-6 Interacts with Glycoprotein F57F4.4 to Cooperatively Regulate the Growth of Caenorhabditis elegans. Biological and Pharmaceutical Bulletin, 2011, 34, 1139-1142.	1.4	16
17	Mammalian galectins bind Galactosel̂²1–4Fucose disaccharide, a unique structural component of protostomial N-type glycoproteins. Biochemical and Biophysical Research Communications, 2013, 436, 509-513.	2.1	16
18	Caenorhabditis elegans proteins captured by immobilized Galβ1-4Fuc disaccharide units: assignment of 3 annexins. Carbohydrate Research, 2011, 346, 1837-1841.	2.3	15

Томонаги Такеисні

#	Article	IF	CITATIONS
19	Structural mechanisms for the Sâ€nitrosylationâ€derived protection of mouse galectinâ€2 from oxidationâ€induced inactivation revealed by NMR. FEBS Journal, 2018, 285, 1129-1145.	4.7	15
20	Identification of the cysteine residue responsible for oxidative inactivation of mouse galectin-2. Journal of Biochemistry, 2016, 160, 233-241.	1.7	14
21	Potential of biocompatible polymeric ultra-thin films, nanosheets, as topical and transdermal drug delivery devices. International Journal of Pharmaceutics, 2019, 565, 41-49.	5.2	14
22	The DC2.3 Gene in Caenorhabditis elegans Encodes a Galectin That Recognizes the Galactose.BETA.1.RAR.4Fucose Disaccharide Unit. Biological and Pharmaceutical Bulletin, 2011, 34, 1635-1639.	1.4	13
23	Identification of Galectin-2–Mucin Interaction and Possible Formation of a High Molecular Weight Lattice. Biological and Pharmaceutical Bulletin, 2017, 40, 1789-1795.	1.4	13
24	Localization and characterization of γ-glutamyl cyclotransferase in cancer cells. Molecular Medicine Reports, 2009, 2, 385-91.	2.4	11
25	Sugar-Binding Properties of the Two Lectin Domains of LEC-1 with Respect to the Gal.BETA.1-4Fuc Disaccharide Unit Present in Protostomia Glycoconjugates. Biological and Pharmaceutical Bulletin, 2011, 34, 1134-1138.	1.4	11
26	Structural basis of preferential binding of fucose-containing saccharide by the Caenorhabditis elegans galectin LEC-6. Glycobiology, 2013, 23, 797-805.	2.5	11
27	N -acetylglucosamine suppresses osteoclastogenesis in part through the promotion of O -GlcNAcylation. Bone Reports, 2016, 5, 15-21.	0.4	11
28	Galactoseβ1â€4fucose: A unique disaccharide unit found in <i>N</i> â€glycans of invertebrates including nematodes. Proteomics, 2016, 16, 3137-3147.	2.2	10
29	ISG15 Regulates RANKL-Induced Osteoclastogenic Differentiation of RAW264 Cells. Biological and Pharmaceutical Bulletin, 2015, 38, 482-486.	1.4	8
30	Potential Interaction between Galectin-2 and MUC5AC in Mouse Gastric Mucus. Biological and Pharmaceutical Bulletin, 2020, 43, 356-360.	1.4	8
31	Galectin-2 suppresses nematode development by binding to the invertebrate-specific galactosel²1-4fucose glyco-epitope. Glycobiology, 2019, 29, 504-512.	2.5	6
32	Galectin-2 Has Bactericidal Effects against Helicobacter pylori in a β-galactoside-Dependent Manner. International Journal of Molecular Sciences, 2020, 21, 2697.	4.1	6
33	Detection and Analysis of Protein ISGylation. , 2008, 446, 139-149.		6
34	Osteoclast Differentiation Is Suppressed by Increased <i>O</i> -GlcNAcylation Due to Thiamet G Treatment. Biological and Pharmaceutical Bulletin, 2020, 43, 1501-1505.	1.4	6
35	Preparation of a polyclonal antibody that recognizes a unique galactoseβ1-4fucose disaccharide epitope. Carbohydrate Research, 2015, 412, 50-55.	2.3	4
36	Cross-Link Formation between Mutant Galectins of Caenorhabditis elegans with a Substituted Cysteine Residue and Asialofetuin via a Photoactivatable Bifunctional Reagent. Biological and Pharmaceutical Bulletin, 2011, 34, 929-932.	1.4	3

Tomoharu Takeuchi

#	Article	IF	CITATIONS
37	Synthesis of New Gal.BETA.1.RAR.4Fuc Segments Useful for Biological Investigations. Chemical and Pharmaceutical Bulletin, 2011, 59, 1307-1310.	1.3	3
38	Crosslinking of Cys-Mutated Human Galectin-1 to the Model Glycoprotein Ligands Asialofetuin and Laminin by Using a Photoactivatable Bifunctional Reagent. Biological and Pharmaceutical Bulletin, 2014, 37, 877-882.	1.4	3
39	Purification of galectin-1 mutants using an immobilized Galactoseβ1–4Fucose affinity adsorbent. Protein Expression and Purification, 2015, 111, 82-86.	1.3	2
40	Galectins in Invertebrates with a focus on <i>Caenorhabditis elegans</i> . Trends in Glycoscience and Glycotechnology, 2018, 30, SE67-SE74.	0.1	2
41	.BETAGalactosidases from Jack Bean and Streptococcus Have Different Cleaving Abilities towards Fucose-Containing Sugars. Biological and Pharmaceutical Bulletin, 2011, 34, 567-569.	1.4	1
42	Galectins in Invertebrates with a focus on <i>Caenorhabditis elegans</i> . Trends in Glycoscience and Glycotechnology, 2018, 30, SJ25-SJ32.	0.1	1
43	An Approach for the Identification of Proteins Modified with ISG15. Methods in Molecular Biology, 2019, 1934, 235-246.	0.9	1
44	Potential UV-Protective Effect of Freestanding Biodegradable Nanosheet-Based Sunscreen Preparations in XPA-Deficient Mice. Pharmaceutics, 2022, 14, 431.	4.5	0